Monrovia, CA (PressExposure) January 07, 2013 -- Dr. Aaron Ciechanover 2004 Nobel Prize Co-Winner and distinguished research professor in the Technion - Israel Institute of Technology in Haifa Will Give The Keynote Address "Intracellular Proteolysis and The Ubiquitin System: From The Backyard to The Center Stage of Biomedicne" at the 3rd Ubiquitin Research and Drug Discovery Conference (Feb 25-26, 2013 Las Vegas, NV)
As a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease.
Among the numerous prizes Aaron Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among many academies, Dr. Ciechanover is a member of the Israeli National Academy of Sciences and Humanities, the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academy of Sciences of the USA and the Institute of Medicine of the National Academies of the USA (Foreign Associate), and the Russian Academy of Sciences (Foreign Member).
The 3rd Ubiquitin Research and Drug Discovery Conference will bring together a 50-50 mix of academic and industry experts from leading affiliations (such as Elan, Millenium, Genentech, Celgene, Onyx, Cal-Tech, Emory University, Harvard, University of Washington, UCLA etc.) to cover many current and relevant aspects of the Ubiquitin Proteasome Structure, Ligases, SUMO and more.
This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and two others: 1) 4th Cancer Targets and Therapeutics 2) 2nd Oncology Partnering and Deal Making
For more information, please visit http://www.gtcbio.com